Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 01, 2015 4:38 PM ET

Biotechnology

Company Overview of T2 Biosystems, Inc.

Company Overview

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications; T2Candida panel for identifying pathogens associated with sepsis; and T2MR Platform, a magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. It is also developing T2Stat, an integrated instrument that provi...

101 Hartwell Avenue

Lexington, MA 02421

United States

Founded in 2006

110 Employees

Phone:

718-491-3400

Fax:

781-357-3080

Key Executives for T2 Biosystems, Inc.

Chief Executive Officer, President and Director
Age: 55
Total Annual Compensation: $380.4K
Chief Financial Officer
Age: 39
Total Annual Compensation: $171.9K
Chief Operating Officer
Age: 56
Total Annual Compensation: $89.8K
Chief Medical Officer
Age: 64
Total Annual Compensation: $228.4K
Chief Scientific Officer
Age: 36
Total Annual Compensation: $274.3K
Compensation as of Fiscal Year 2014.

T2 Biosystems, Inc. Key Developments

T2 Biosystems, Inc. Announces the Results of Two Investigational Studies Highlighting the Capability of its T2 Magnetic Resonance Detector to Accurately and Rapidly Measure Hemostasis Parameters Directly in Whole Blood

T2 Biosystems, Inc. announced the results of two investigational studies highlighting the capability of its T2 Magnetic Resonance detector to accurately and rapidly measure hemostasis parameters directly in whole blood. In both studies, T2MR demonstrated strong correlation to a current standard of care, while doing so on a single instrument suitable for point of care testing, drug development, animal studies, and biomarker discovery. The results were presented at the International Society on Thrombosis and Haemostasis 2015 Congress in Toronto, Canada. T2MR Platelet Analysis Correlates with Light Transmission Aggregometry and Rapidly Reveals Unique Details of ADP-Mediated Platelet Activation in Whole Blood: The current standard of care for measuring platelet activation, an important factor in making therapeutic, surgical, and transfusion decisions, generally requires specialized laboratories and personnel, large volumes of blood and takes approximately three hours to obtain a result. In this study, T2MR detected the most clinically valuable platelet parameters to provide an assessment of platelet activity in just 20 minutes using low blood volumes while demonstrating 100% correlation to the current standard of care. Whole Blood Platelet Activity Measurements Multiplexed with Quantitative Fibrinogen, Clot Time and Fibrinolysis Measurements by T2MR: Currently, there is no single solution for rapidly measuring the four key measures of coagulation: clotting time, platelet function, fibrinogen and fibrinolysis. These measures together are critical for determining patient risk for clotting or bleeding. In this study, T2MR was shown to rapidly and accurately assess potential bleeding disorders through a single multiplex analysis of global hemostasis utilizing low blood volumes. In addition, T2MR generated robust signatures that have led to the discovery of novel biomarkers that may potentially have other important clinical applications.

T2 Biosystems, Inc. Announces Board Changes

On June 19, 2015, T2 Biosystems, Inc. received a written letter of resignation from Alan Crane stating that he resigned, effective immediately prior to the company's 2015 Annual Stockholder Meeting held on June 19, 2015, from his position as a Class I member of the Board of Directors of the company. Mr. Crane resigned from the Board to pursue other business opportunities and not as a result of any dispute or disagreement with the company or any member of its management. Mr. Crane served on the company's Compensation Committee prior to his resignation. Following Mr. Crane's resignation from the Board, the Compensation Committee is now comprised of the following members of the Board: Stanley Lapidus (Chairman) and Thomas Carella.

T2 Biosystems, Inc. Presents at BIO International Convention 2015, Jun-15-2015 through Jun-18-2015

T2 Biosystems, Inc. Presents at BIO International Convention 2015, Jun-15-2015 through Jun-18-2015. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Presentation Date & Speakers: Jun-17-2015, John P. McDonough, Chief Executive Officer, President and Director. Jun-18-2015, Thomas J. Lowery, Chief Scientific Officer.

Similar Private Companies By Industry

Company Name Region
Profectus Biosciences, Inc. United States
Virun, Inc. United States
Avantome, Inc. United States
Nimbus Therapeutics, Inc. United States
Verax Biomedical, Incorporated United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact T2 Biosystems, Inc., please visit www.t2biosystems.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.